The newest white paper in Symbio’s white paper series was recently released entitled, “Atopic Dermatitis: Considerations for Clinical Trials.” This paper explores the clinical research challenges involved in AD trials including lack of standardized rating scales, the need to enroll children and young people, and the impact of time of year and geographic region.
Atopic dermatitis (AD), often called eczema, is a common and often debilitating skin condition whose root cause remains unknown but is likely to be related to allergies and immune dysregulation. No curative treatment exists for this condition and management usually consists of topical corticosteroids. In more severe cases, topical calcineurin inhibitors, biologics or immunosuppressants may be necessary. Unless remission occurs, AD is a chronic disease and needs to be suppressed through medication and vigorous hygiene practices.
AD’s prevalence, lack of cure, and impact on life quality have driven continuous research and investment into novel therapies. Unless an extremely tolerable and efficacious treatment becomes available, this trend is likely to continue.
